Acelyrin
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $300M
Overview
A clinical-stage company rapidly developing biologic therapies for severe immunologic conditions.
Immunology
Technology Platform
A development-focused model leveraging clinical and regulatory expertise to advance in-licensed biologic candidates, particularly monoclonal antibodies, in immunology.
Funding History
1Total raised:$300M
Venture$300M
Opportunities
Potential for rapid market penetration and significant revenue if its lead Phase 3 candidate demonstrates best-in-class profile in a large inflammatory disease market.
Risk Factors
Clinical or regulatory setbacks with its lead asset, which represents the bulk of the company's valuation and near-term prospects.
Competitive Landscape
Competes directly with large pharmaceutical companies that dominate the immunology market with established, often first-in-class, biologic therapies.